These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 3820681

  • 1. [Contrast-enhanced MRI and contrast medium development].
    Iio M.
    Nihon Rinsho; 1987 Jan; 45(1):28-32. PubMed ID: 3820681
    [No Abstract] [Full Text] [Related]

  • 2. The role of gadolinium-diethylenetriaminepentaacetic acid in the evaluation of the central nervous system.
    Runge VM, Gelblum DY.
    Magn Reson Q; 1990 Apr; 6(2):85-107. PubMed ID: 2202425
    [No Abstract] [Full Text] [Related]

  • 3. [The enhancement effects of Gd-DTPA for cerebrospinal lesions-- comparison with conventional T2-weighted images].
    Mano I, Yoshida H, Kono T, Tsuchida T, Terao H, Iio M.
    Rinsho Hoshasen; 1987 Dec; 32(13):1547-53. PubMed ID: 3448287
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Gadolinium-DTPA (Magnevist) as contrast medium for galactography].
    Kaltenborn H, Schadmand S, Beck T, Thelen M.
    Rofo; 1995 Nov; 163(5):457-9. PubMed ID: 8527765
    [No Abstract] [Full Text] [Related]

  • 7. Future applications of contrast agents for magnetic resonance imaging of the central nervous system.
    Bradley WG.
    Invest Radiol; 1992 Aug; 27 Suppl 1():S58-60. PubMed ID: 1506155
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging.
    Gonzalez-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH.
    Ann Neurol; 1987 Mar; 21(3):300-6. PubMed ID: 3606036
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Oral contrast medium for magnetic resonance tomography of the abdomen. II. Phase I clinical testing of gadolinium-DTPA].
    Kornmesser W, Laniado M, Hamm B, Clauss W, Weinmann HJ, Schulz E, Wolf KJ, Felix R.
    Rofo; 1987 Nov; 147(5):550-6. PubMed ID: 2825293
    [Abstract] [Full Text] [Related]

  • 12. Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen.
    Kabalka G, Buonocore E, Hubner K, Moss T, Norley N, Huang L.
    Radiology; 1987 Apr; 163(1):255-8. PubMed ID: 3454163
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Technical advances in magnetic resonance imaging.
    Bydder GM.
    Curr Opin Neurol Neurosurg; 1992 Dec; 5(6):854-8. PubMed ID: 1467578
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hepatic haemangioma: dynamic MRI using gadolinium-DTPA.
    Ohtomo K, Itai Y, Yoshikawa K, Kokubo T, Yashiro N, Iio M.
    Eur J Radiol; 1987 Nov; 7(4):257-9. PubMed ID: 3691543
    [Abstract] [Full Text] [Related]

  • 17. [Acoustic neurinomas. Magnetic resonance tomography using the contrast medium Gd-DTPA].
    Pronin IN, Kornienko VN.
    Zh Vopr Neirokhir Im N N Burdenko; 1995 Nov; (2):16-7. PubMed ID: 7625134
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [MRI of the nasopharynx with Gd-DTPA: its value and differential diagnostic criteria].
    Vogl T, Dresel S, Schedel H, Markl A, Grevers G, Stelzer S, Lissner J.
    Rofo; 1989 May; 150(5):516-22. PubMed ID: 2541475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.